Last $5.20 USD
Change Today 0.00 / 0.00%
Volume 87.5K
RTIX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

rti surgical inc (RTIX) Snapshot

Open
$5.22
Previous Close
$5.20
Day High
$5.40
Day Low
$5.08
52 Week High
12/9/14 - $5.67
52 Week Low
02/5/14 - $3.00
Market Cap
295.9M
Average Volume 10 Days
159.4K
EPS TTM
$0.01
Shares Outstanding
56.9M
EX-Date
--
P/E TM
435.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for RTI SURGICAL INC (RTIX)

rti surgical inc (RTIX) Related Bloomberg News

View More Bloomberg News

rti surgical inc (RTIX) Related Businessweek News

No Related Businessweek News Found

rti surgical inc (RTIX) Details

RTI Surgical, Inc., together with its subsidiaries, produces and sells orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. It processes donated human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera, and dermal tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by utilizing its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company’s implants are used in the fields of spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental, and ortho fixation. RTI Surgical, Inc. markets its products through its direct distribution force, as well as through a network of independent distributors to hospitals and surgeons in the United States and internationally. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.

1,100 Employees
Last Reported Date: 03/10/14
Founded in 1997

rti surgical inc (RTIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $547.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $332.3K
Executive Vice President of North American Sa...
Total Annual Compensation: $327.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $330.1K
Executive Vice President of Administration an...
Total Annual Compensation: $328.4K
Compensation as of Fiscal Year 2013.

rti surgical inc (RTIX) Key Developments

RTI Surgical Inc. Announces Thomas F. Rose to Retire as Executive Vice President of Administration, Effective Dec. 31, 2014

RTI Surgical Inc. announced that Thomas F. Rose has informed the company of his intention to retire from his position as executive vice president of administration effective Dec. 31, 2014. Rose will continue to serve as corporate secretary for RTI’s board of directors.

RTI Surgical Inc. Announces Publication a Study Highlighting the Clinical Results of its nanOss Product

RTI Surgical Inc. announced the publication a study highlighting the clinical results of its nanOss product, an advanced bone graft substitute that is composed of nano-structured hydroxyapatite granules and an open structured engineered collagen carrier. The retrospective, multi-center study was published in The Journal of Spinal Disorders & Techniques, demonstrated equivalent fusion rates by utilizing nanOss to iliac crest autograft in the lumbar spine.

RTI Surgical Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Full Year Ended December 31, 2014; Provides Earnings Guidance for the Fourth Quarter Ended December 31, 2014

RTI Surgical Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues of $65,163,000 against $54,742,000 a year ago. Operating income was $3,606,000 against operating loss of $13,598,000 a year ago. Income before income tax expense was $3,310,000 against loss before income tax benefit of $13,594,000 a year ago. Net income applicable to common shares was $1,202,000 or $0.02 per basic and diluted share against loss of $9,125,000 or $0.16 per basic and diluted share a year ago. Adjusted net income applicable to common shares was $1,502,000 or $0.03 per basic and diluted share against loss of $699,000 or $0.01 per basic and diluted share a year ago. Net cash provided by operating activities was $2,149,000 against net cash used in operating activities of $7,086,000 a year ago. Purchases of property, plant and equipment was $2,800,000 against $6,282,000 a year ago. For the nine months, the company reported revenues of $191,937,000 against $137,473,000 a year ago. Operating income was $4,528,000 against operating loss of $16,831,000 a year ago. Income before income tax expense was $3,392,000 against loss before income tax benefit of $16,824,000 a year ago. Net income applicable to common shares was $281,000 or $0.00 per basic and diluted share against loss of $10,662,000 or $0.19 per basic and diluted share a year ago. Adjusted net income applicable to common shares was $3,486,000 or $0.06 per basic and diluted share against loss of $494,000 or $0.01 per basic and diluted share a year ago. Net cash provided by operating activities was $1,464,000 against net cash used in operating activities of $11,870,000 a year ago. Purchases of property, plant and equipment was $11,272,000 against $11,154,000 a year ago. For the fourth quarter ended December 31, 2014, the company expects revenues to be between $68 million and $69 million and net income per fully diluted common share to be approximately $0.04, based on 57.5 million fully diluted shares outstanding. Adjusted non-GAAP net income per diluted common share is expected to be $0.04. For the full year ended December 31, 2014, the company expects net income per fully diluted common share to be approximately $0.04, based on 57.4 million fully diluted shares outstanding. Based on results from the first three quarters of the year, the company is narrowing its full year revenue guidance for 2014. The company now expects full year revenues for 2014 to be between $260 million and $261 million, as compared to prior guidance of between $258 million and $261 million. On an adjusted basis, excluding a first quarter inventory purchase accounting adjustment and a third quarter severance charge, the company expects full year adjusted net income per fully diluted common share to be approximately $0.11 based on 57.4 million fully diluted common shares outstanding, as compared to prior guidance of $0.09 to $0.11. For 2014, the company anticipates being cash flow positive from operations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTIX:US $5.20 USD 0.00

RTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alphatec Holdings Inc $1.27 USD -0.06
Bacterin International Holdings Inc $2.59 USD -0.02
Exactech Inc $22.68 USD +0.24
ICU Medical Inc $83.38 USD +1.63
Orthofix International NV $30.81 USD +0.36
View Industry Companies
 

Industry Analysis

RTIX

Industry Average

Valuation RTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.2x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RTI SURGICAL INC, please visit www.rtisurgical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.